跳到主要內容

臺灣博碩士論文加值系統

(34.226.244.254) 您好!臺灣時間:2021/08/03 00:33
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:余品柔
研究生(外文):Ping-Jou Yu
論文名稱:探討細胞激素visfatin在乳房癌化發展過程所扮演之角色
論文名稱(外文):Visfatin, an adipocytokine in breast tumorigenesis
指導教授:呂世正
指導教授(外文):Shr-Jeng Leu
學位類別:碩士
校院名稱:國立陽明大學
系所名稱:醫學生物技術暨檢驗學系暨研究所
學門:醫藥衛生學門
學類:醫學技術及檢驗學類
論文種類:學術論文
論文出版年:2009
畢業學年度:97
語文別:中文
論文頁數:123
中文關鍵詞:脂肪激素乳癌重組蛋白
外文關鍵詞:adipocytokinevisfatinbreast cancersinvasionMAPK
相關次數:
  • 被引用被引用:0
  • 點閱點閱:136
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
脂肪細胞激素visfatin是一個具多重功能的蛋白質。透過生物資訊的資料庫分析,我們發現在數個人類癌症的腫瘤組織及癌細胞的基因表達資料庫中,相較於正常組織,visfatin表達量在癌組織內有高度表達的趨勢;相關研究亦顯示visfatin是個受缺氧調控的基因,同時也可以促進血管新生;因此,我們推斷visfatin與腫瘤的增生有高度的關聯性。進一步地分析數種癌細胞株,我們發現乳癌細胞無論是內生性或是分泌至培養液中的visfatin其表現量皆與乳癌細胞株的惡性程度呈現正相關;visfatin是個值得深入探討是否為導致人類乳癌發生的重要基因。透過桿狀病毒蛋白表達系統 ( baculovirus expression system ) 純化出具有生物活性的visfatin重組蛋白,以進一步釐清visfaitn於人類癌症惡化時的分子機制。以我們所純化的visfatin重組蛋白刺激乳癌細胞,visfatin可於很短暫的時間內活化細胞內訊息分子 (MAPK kinase cascade)。此外,visfatin還具有促進癌細胞移動 (migration) 以及侵襲 (invasion) 的能力,而且當我們以激酶抑制劑分別阻斷其訊息路徑時,由visfatin所誘發的細胞反應也隨之受到抑制。其結果也間接的說明這些細胞的表面可能存在未知的受體,可以接收並傳遞visfatin的信息。我們進一步地利用biotinylated visfatin以研究細胞表面可能與visfatin 結合的分子,透過蛋白質體的篩選分析找出癌細胞表面的visfatin受體分子。

本研究闡明visfatin調控乳癌細胞訊息傳導的分子機制,為未來治療乳癌以及其他相關的疾病提供另一個可能策略。
Visfatin, an adipocytokine, is a newly identified cytokine of multiple functions. Based on our preliminary bioinformatic analyses, expression of visfatin was found to be significantly increased in various human cancers by over 5-20 folds as compared with the normal counterparts. This gene is not well characterized yet in tumorigenesis. The recent reports also indicate that visfatin is hypoxia-inducible and an angiogenesis inducer. We have confirmed the expression of visfatin correlates with cancer malignancy and secretion of visfatin protein in human breast caner cell lines. Thus, visfatin appears to be an excellent candidate gene potentially involved in breast cancers. In order to elucidate the molecular actions of visfatin, we are the first and have successfully generated recombinant visfatin proteins using our established baculovirus-expressing system in a special protein secretion strategy. We can obtain the high-yield and high-purity recombinant visfatin from conditioned medium and followed by sequential affinity chromatographies. Upon addition of recombinant visfatin to breast cancer cells, the PI3K, Akt, Erk1/2, and STAT-3 phophorylation events can be rapidly induced within minutes. Moreover, visfatin induces cancer cell migration as well as cell invasion. In addition, inhibitors of PI3K and MAPK block the visfatin-mediated cellular activities. By generating the recombinant visfatin with a specific biotin labeling and track down its route, our data indicate that a putative specific receptor may exist for visfatin actions. We are setting up systemic screenings to isolate visfatin-interacting receptor.
Understanding the molecular mechanism underlying the actions of visfatin may help design targeting strategies to human breast cancers and relevant diseases.
中文摘要 iii
Abstract iv
目次 v
壹、 緒論 1
貳、論文研究動機與目的 7
參、實驗材料與方法 9
肆、實驗結果 65
伍、實驗討論 84
陸、參考文獻 87
柒、實驗圖表 96
捌、附錄 114
1. Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Matsuki, Y., Murakami, M., Ichisaka, T., Murakami, H., et al. 2005. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426-430.
2. Samal, B., Sun, Y., Stearns, G., Xie, C., Suggs, S., and McNiece, I. 1994. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14:1431-1437.
3. Krzysik-Walker, S.M., Ocon-Grove, O.M., Maddineni, S.R., Hendricks, G.L., 3rd, and Ramachandran, R. 2008. Is visfatin an adipokine or myokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens. Endocrinology 149:1543-1550.
4. Xie, H., Tang, S.Y., Luo, X.H., Huang, J., Cui, R.R., Yuan, L.Q., Zhou, H.D., Wu, X.P., and Liao, E.Y. 2007. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 80:201-210.
5. Dahl, T.B., Yndestad, A., Skjelland, M., Oie, E., Dahl, A., Michelsen, A., Damas, J.K., Tunheim, S.H., Ueland, T., Smith, C., et al. 2007. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. In Circulation. 972-980.
6. Song, H.K., Lee, M.H., Kim, B.K., Park, Y.G., Ko, G.J., Kang, Y.S., Han, J.Y., Han, S.Y., Han, K.H., Kim, H.K., et al. 2008. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 295:F1485-1494.
7. Morgan, S.A., Bringolf, J.B., and Seidel, E.R. 2008. Visfatin expression is elevated in normal human pregnancy. Peptides 29:1382-1389.
8. Haider, D.G., Schaller, G., Kapiotis, S., Maier, C., Luger, A., and Wolzt, M. 2006. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49:1909-1914.
9. Pagano, C., Pilon, C., Olivieri, M., Mason, P., Fabris, R., Serra, R., Milan, G., Rossato, M., Federspil, G., and Vettor, R. 2006. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91:3165-3170.
10. Briana, D.D., Boutsikou, M., Gourgiotis, D., Kontara, L., Baka, S., Iacovidou, N., Hassiakos, D., and Malamitsi-Puchner, A. 2007. Role of visfatin, insulin-like growth factor-I and insulin in fetal growth. J Perinat Med 35:326-329.
11. Chan, T.F., Chen, Y.L., Lee, C.H., Chou, F.H., Wu, L.C., Jong, S.B., and Tsai, E.M. 2006. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig 13:364-367.
12. Chen, M.P., Chung, F.M., Chang, D.M., Tsai, J.C., Huang, H.F., Shin, S.J., and Lee, Y.J. 2006. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91:295-299.
13. Curat, C.A., Wegner, V., Sengenes, C., Miranville, A., Tonus, C., Busse, R., and Bouloumie, A. 2006. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49:744-747.
14. Haider, D.G., Holzer, G., Schaller, G., Weghuber, D., Widhalm, K., Wagner, O., Kapiotis, S., and Wolzt, M. 2006. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 43:548-549.
15. Krzyzanowska, K., Krugluger, W., Mittermayer, F., Rahman, R., Haider, D., Shnawa, N., and Schernthaner, G. 2006. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 110:605-609.
16. Li, L., Yang, G., Li, Q., Tang, Y., Yang, M., Yang, H., and Li, K. 2006. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 114:544-548.
17. Otero, M., Lago, R., Gomez, R., Lago, F., Dieguez, C., Gomez-Reino, J.J., and Gualillo, O. 2006. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65:1198-1201.
18. Wen, Y., Wang, H.W., Wu, J., Lu, H.L., Hu, X.F., and Cianflone, K. 2006. Effects of fatty acid regulation on visfatin gene expression in adipocytes. Chin Med J (Engl) 119:1701-1708.
19. Axelsson, J., Witasp, A., Carrero, J.J., Qureshi, A.R., Suliman, M.E., Heimburger, O., Barany, P., Lindholm, B., Alvestrand, A., Schalling, M., et al. 2007. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 49:237-244.
20. Dogru, T., Sonmez, A., Tasci, I., Bozoglu, E., Yilmaz, M.I., Genc, H., Erdem, G., Gok, M., Bingol, N., Kilic, S., et al. 2007. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 76:24-29.
21. Fernandez-Real, J.M., Moreno, J.M., Chico, B., Lopez-Bermejo, A., and Ricart, W. 2007. Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance. Diabetes Care 30:616-621.
22. Filippatos, T.D., Derdemezis, C.S., Kiortsis, D.N., Tselepis, A.D., and Elisaf, M.S. 2007. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 30:323-326.
23. Korner, A., Bottcher, Y., Enigk, B., Kiess, W., Stumvoll, M., and Kovacs, P. 2007. Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children. Metabolism 56:772-777.
24. MacLaren, R., Cui, W., and Cianflone, K. 2007. Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Metab 9:490-497.
25. Sethi, J.K. 2007. Is PBEF/visfatin/Nampt an authentic adipokine relevant to the metabolic syndrome? Curr Hypertens Rep 9:33-38.
26. Takebayashi, K., Suetsugu, M., Wakabayashi, S., Aso, Y., and Inukai, T. 2007. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 56:451-458.
27. Tanaka, T., and Nabeshima, Y. 2007. Nampt/PBEF/Visfatin: a new player in beta cell physiology and in metabolic diseases? Cell Metab 6:341-343.
28. Pfutzner, A., Marx, N., Walcher, D., Lobig, M., Seidel, D., and Forst, T. 2008. Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease. Clin Lab 54:237-241.
29. Retnakaran, R., Youn, B.S., Liu, Y., Hanley, A.J., Lee, N.S., Park, J.W., Song, E.S., Vu, V., Kim, W., Tungtrongchitr, R., et al. 2008. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf) 69:885-893.
30. Tilg, H., and Moschen, A.R. 2008. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 114:275-288.
31. Zhu, J., Schott, M., Liu, R., Liu, C., Shen, B., Wang, Q., Mao, X., Xu, K., Wu, X., Schinner, S., et al. 2008. Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes. Horm Metab Res 40:801-805.
32. Blakemore, A.I., Meyre, D., Delplanque, J., Vatin, V., Lecoeur, C., Marre, M., Tichet, J., Balkau, B., Froguel, P., and Walley, A.J. 2009. A Rare Variant in the Visfatin Gene (NAMPT/PBEF1) Is Associated With Protection From Obesity. Obesity (Silver Spring).
33. Peter Belenky. 2006. NAD+ metabolism in health and disease. TRENDS in Biochemical Sciences.
34. Wang, T., Zhang, X., Bheda, P., Revollo, J.R., Imai, S., and Wolberger, C. 2006. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol 13:661-662.
35. Yang, H., Lavu, S., and Sinclair, D.A. 2006. Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity? Exp Gerontol 41:718-726.
36. Revollo, J.R., Grimm, A.A., and Imai, S. 2007. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 23:164-170.
37. Revollo, J.R., Korner, A., Mills, K.F., Satoh, A., Wang, T., Garten, A., Dasgupta, B., Sasaki, Y., Wolberger, C., Townsend, R.R., et al. 2007. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6:363-375.
38. Skokowa, J., Lan, D., Thakur, B.K., Wang, F., Gupta, K., Cario, G., Brechlin, A.M., Schambach, A., Hinrichsen, L., Meyer, G., et al. 2009. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med 15:151-158.
39. Lamming, D.W., Latorre-Esteves, M., Medvedik, O., Wong, S.N., Tsang, F.A., Wang, C., Lin, S.J., and Sinclair, D.A. 2005. HST2 mediates SIR2-independent life-span extension by calorie restriction. Science 309:1861-1864.
40. Araki, T., Sasaki, Y., and Milbrandt, J. 2004. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305:1010-1013.
41. Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., and Puigserver, P. 2005. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434:113-118.
42. Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado De Oliveira, R., Leid, M., McBurney, M.W., and Guarente, L. 2004. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429:771-776.
43. Luo, J., Nikolaev, A.Y., Imai, S., Chen, D., Su, F., Shiloh, A., Guarente, L., and Gu, W. 2001. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107:137-148.
44. Anderson, R.M. 2003. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature.
45. Guarente, L. 2005. Calorie Restriction— the SIR2 Connection. Cell.
46. Kim, M.M., Yoon, S.O., Cho, Y.S., and Chung, A.S. 2004. Histone deacetylases, HDAC1 and HSIR2, act as a negative regulator of ageing through p53 in human gingival fibroblast. Mech Ageing Dev 125:351-357.
47. Vaziri, H., Dessain, S.K., Ng Eaton, E., Imai, S.I., Frye, R.A., Pandita, T.K., Guarente, L., and Weinberg, R.A. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149-159.
48. Brunet, A., Sweeney, L.B., Sturgill, J.F., Chua, K.F., Greer, P.L., Lin, Y., Tran, H., Ross, S.E., Mostoslavsky, R., Cohen, H.Y., et al. 2004. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303:2011-2015.
49. van der Horst, A., Tertoolen, L.G., de Vries-Smits, L.M., Frye, R.A., Medema, R.H., and Burgering, B.M. 2004. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem 279:28873-28879.
50. Motta, M.C., Divecha, N., Lemieux, M., Kamel, C., Chen, D., Gu, W., Bultsma, Y., McBurney, M., and Guarente, L. 2004. Mammalian SIRT1 represses forkhead transcription factors. Cell 116:551-563.
51. Daitoku, H., Hatta, M., Matsuzaki, H., Aratani, S., Ohshima, T., Miyagishi, M., Nakajima, T., and Fukamizu, A. 2004. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci U S A 101:10042-10047.
52. Bouras, T., Fu, M., Sauve, A.A., Wang, F., Quong, A.A., Perkins, N.D., Hay, R.T., Gu, W., and Pestell, R.G. 2005. SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem 280:10264-10276.
53. Balaban, R.S., Nemoto, S., and Finkel, T. 2005. Mitochondria, oxidants, and aging. Cell 120:483-495.
54. Bitterman, K.J., Anderson, R.M., Cohen, H.Y., Latorre-Esteves, M., and Sinclair, D.A. 2002. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 277:45099-45107.
55. Matsui, H., Tsutsumi, A., Sugihara, M., Suzuki, T., Iwanami, K., Kohno, M., Goto, D., Matsumoto, I., Ito, S., and Sumida, T. 2008. Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis. Ann Rheum Dis 67:571-572.
56. Wosikowski, K., Mattern, K., Schemainda, I., Hasmann, M., Rattel, B., and Loser, R. 2002. WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. Cancer Res 62:1057-1062.
57. Hasmann, M., and Schemainda, I. 2003. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63:7436-7442.
58. Kang, G.B., Bae, M.H., Kim, M.K., Im, I., Kim, Y.C., and Eom, S.H. 2009. Crystal structure of Rattus norvegicus Visfatin/PBEF/Nampt in complex with an FK866-based inhibitor. Mol Cells.
59. Muruganandham, M., Alfieri, A.A., Matei, C., Chen, Y., Sukenick, G., Schemainda, I., Hasmann, M., Saltz, L.B., and Koutcher, J.A. 2005. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res 11:3503-3513.
60. Drevs, J., Loser, R., Rattel, B., and Esser, N. 2003. Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res 23:4853-4858.
61. Fasshauer, M., Bluher, M., Stumvoll, M., Tonessen, P., Faber, R., and Stepan, H. 2007. Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. Clin Endocrinol (Oxf) 66:434-439.
62. Mastorakos, G., Valsamakis, G., Papatheodorou, D.C., Barlas, I., Margeli, A., Boutsiadis, A., Kouskouni, E., Vitoratos, N., Papadimitriou, A., Papassotiriou, I., et al. 2007. The role of adipocytokines in insulin resistance in normal pregnancy: visfatin concentrations in early pregnancy predict insulin sensitivity. Clin Chem 53:1477-1483.
63. Fasshauer, M., Waldeyer, T., Seeger, J., Schrey, S., Ebert, T., Kratzsch, J., Lossner, U., Bluher, M., Stumvoll, M., Faber, R., et al. 2008. Serum levels of the adipokine visfatin are increased in pre-eclampsia. Clin Endocrinol (Oxf) 69:69-73.
64. Telejko, B., Kuzmicki, M., Zonenberg, A., Szamatowicz, J., Wawrusiewicz-Kurylonek, N., Nikolajuk, A., Kretowski, A., and Gorska, M. 2009. Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue. Diabetes Res Clin Pract 84:68-75.
65. Yonezawa, T. 2006. Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway. Federation of European Biochemical Societies.(FEBS).
66. Hu, W., Wang, Z., Wang, H., Huang, H., and Dong, M. 2008. Serum visfatin levels in late pregnancy and pre-eclampsia. Acta Obstet Gynecol Scand 87:413-418.
67. Mazaki-Tovi, S., Romero, R., Kusanovic, J.P., Vaisbuch, E., Erez, O., Than, N.G., Chaiworapongsa, T., Nhan-Chang, C.L., Pacora, P., Gotsch, F., et al. 2009. Maternal visfatin concentration in normal pregnancy. J Perinat Med 37:206-217.
68. Dahl, T.B., Yndestad, A., Skjelland, M., Oie, E., Dahl, A., Michelsen, A., Damas, J.K., Tunheim, S.H., Ueland, T., Smith, C., et al. 2007. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115:972-980.
69. Liu, S.W., Qiao, S.B., Yuan, J.S., and Liu, D.Q. 2008. Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans. Clin Endocrinol (Oxf).
70. Filippatos, T.D., Randeva, H.S., Derdemezis, C.S., Elisaf, M.S., and Mikhailidis, D.P. VISFATIN/PBEF and Atherosclerosis-Related Diseases. Curr Vasc Pharmacol.
71. Yilmaz, M.I., Saglam, M., Carrero, J.J., Qureshi, A.R., Caglar, K., Eyileten, T., Sonmez, A., Cakir, E., Yenicesu, M., Lindholm, B., et al. 2008. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 23:959-965.
72. de Boer, J.F., Bahr, M.J., Boker, K.H., Manns, M.P., and Tietge, U.J. 2009. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 296:G196-201.
73. Shen, C.J., Tsai, E.M., Lee, J.N., Chen, Y.L., Lee, C.H., and Chan, T.F. 2009. The concentrations of visfatin in the follicular fluids of women undergoing controlled ovarian stimulation are correlated to the number of oocytes retrieved. Fertil Steril.
74. Kim, S.R., Bae, S.K., Choi, K.S., Park, S.Y., Jun, H.O., Lee, J.Y., Jang, H.O., Yun, I., Yoon, K.H., Kim, Y.J., et al. 2007. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 357:150-156.
75. Adya, R., Tan, B.K., Chen, J., and Randeva, H.S. 2008. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care 31:758-760.
76. Adya, R., Tan, B.K., Punn, A., Chen, J., and Randeva, H.S. 2008. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 78:356-365.
77. Bae, Y.H., Bae, M.K., Kim, S.R., Lee, J.H., Wee, H.J., and Bae, S.K. 2009. Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. Biochem Biophys Res Commun 379:206-211.
78. Lago, F. 2007. Adipokines as emerging mediators of immune response and inflammation. Nature.
79. Moschen, A.R., Kaser, A., Enrich, B., Mosheimer, B., Theurl, M., Niederegger, H., and Tilg, H. 2007. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178:1748-1758.
80. Tsiotra, P.C., Tsigos, C., Yfanti, E., Anastasiou, E., Vikentiou, M., Psarra, K., Papasteriades, C., and Raptis, S.A. 2007. Visfatin, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res 39:758-763.
81. Li, Y., Zhang, Y., Dorweiler, B., Cui, D., Wang, T., Woo, C.W., Brunkan, C.S., Wolberger, C., Imai, S., and Tabas, I. 2008. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem 283:34833-34843.
82. Luk, T., Malam, Z., and Marshall, J.C. 2008. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 83:804-816.
83. Van Beijnum, J.R., Moerkerk, P.T., Gerbers, A.J., De Bruine, A.P., Arends, J.W., Hoogenboom, H.R., and Hufton, S.E. 2002. Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer 101:118-127.
84. Nemeth, E., Tashima, L.S., Yu, Z., and Bryant-Greenwood, G.D. 2000. Fetal membrane distention: I. Differentially expressed genes regulated by acute distention in amniotic epithelial (WISH) cells. Am J Obstet Gynecol 182:50-59.
85. Pan, Y.S., Lee, Y.S., Lee, Y.L., Lee, W.C., and Hsieh, S.Y. 2006. Differentially profiling the low-expression transcriptomes of human hepatoma using a novel SSH/microarray approach. BMC Genomics 7:131.
86. Fischer, K., Frohling, S., Scherer, S.W., McAllister Brown, J., Scholl, C., Stilgenbauer, S., Tsui, L.C., Lichter, P., and Dohner, H. 1997. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. Blood 89:2036-2041.
87. Zeng, W.R., Watson, P., Lin, J., Jothy, S., Lidereau, R., Park, M., and Nepveu, A. 1999. Refined mapping of the region of loss of heterozygosity on the long arm of chromosome 7 in human breast cancer defines the location of a second tumor suppressor gene at 7q22 in the region of the CUTL1 gene. Oncogene 18:2015-2021.
88. Tonon, G., Gehlhaus, K.S., Yonescu, R., Kaye, F.J., and Kirsch, I.R. 2004. Multiple reciprocal translocations in salivary gland mucoepidermoid carcinomas. Cancer Genet Cytogenet 152:15-22.
89. Bae, S.K., Kim, S.R., Kim, J.G., Kim, J.Y., Koo, T.H., Jang, H.O., Yun, I., Yoo, M.A., and Bae, M.K. 2006. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 580:4105-4113.
90. Segawa, K., Fukuhara, A., Hosogai, N., Morita, K., Okuno, Y., Tanaka, M., Nakagawa, Y., Kihara, S., Funahashi, T., Komuro, R., et al. 2006. Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism. Biochem Biophys Res Commun 349:875-882.
91. Hagemann, T., Robinson, S.C., Schulz, M., Trumper, L., Balkwill, F.R., and Binder, C. 2004. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 25:1543-1549.
92. Adya, R., Tan, B.K., Chen, J., and Randeva, H.S. 2009. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis 205:113-119.
93. Kim, D., Kim, S., Koh, H., Yoon, S.O., Chung, A.S., Cho, K.S., and Chung, J. 2001. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J 15:1953-1962.
94. Yoeli-Lerner, M., and Toker, A. 2006. Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5:603-605.
95. Chin, Y.R., and Toker, A. 2009. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal 21:470-476.
96. Malyszko, J., Malyszko, J.S., and Mysliwiec, M. 2009. Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients. Transplant Proc 41:150-153.
97. Liu, S.W., Qiao, S.B., Yuan, J.S., and Liu, D.Q. 2009. Visfatin stimulates production of monocyte chemotactic protein-1 and interleukin-6 in human vein umbilical endothelial cells. Horm Metab Res 41:281-286.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊